Acute on chronic liver failure (ACLF) is a syndrome which is characterised by acute decompensation of chronic liver disease. Many ACLF patients are inherently vulnerable, as the most common underlying causes are alcoholic and chronic viral hepatitis. While global chronic viral hepatitis rates continue to rise, there is currently no specific medical treatment for ACLF. Consequently, ACLF is associated with organ failure and devastatingly high 28-day mortality rates between 25-75%. TAK-242 is an innovative, novel treatment option which aims to address unmet clinical need and improve short-term survival rates.